Trial reportJournal of the American College of Cardiology2013
Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.
Trial report in Journal of the American College of Cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07761728 (Comparative Evaluation of 18F-Flurpiridaz and 82Rb-Chloride PET Myocardial Perfusion Imaging), which is not on this map. Cited by 91 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Evaluation of 18F-Flurpiridaz and 82Rb-Chloride PET Myocardial Perfusion Imaging: The FLARE (Flurpiridaz vs. Rubidium Evaluation) Trial
Who cites it
91 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- Improved assessment of coronary artery disease in obese patients with flurpiridaz-Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2026Trial
- Utility ofCirculation. Cardiovascular imaging · 2025Trial
- Subendocardial quantification enhances coronary artery disease detection inEuropean journal of nuclear medicine and molecular imaging · 2025Trial
- Automatic motion correction for myocardial blood flow estimation improves diagnostic performance for coronary artery disease inJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2025Trial
- 18F-flurpiridaz positron emission tomography segmental and territory myocardial blood flow metrics: incremental value beyond perfusion for coronary artery disease categorization.European heart journal. Cardiovascular Imaging · 2022Trial
- Improved myocardial blood flow estimation with residual activity correction and motion correction inEuropean journal of nuclear medicine and molecular imaging · 2022Trial
- Added value of myocardial blood flow usingJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Trial
- Diagnostic Performance of PET Versus SPECT Myocardial Perfusion Imaging in Patients with Smaller Left Ventricles: A Substudy of theJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- Accuracy of Computed Tomographic Angiography and Single-Photon Emission Computed Tomography-Acquired Myocardial Perfusion Imaging for the Diagnosis of Coronary Artery Disease.Circulation. Cardiovascular imaging · 2015Trial
- Review
- First Post-Approval Clinical Use of F-18 Flurpiridaz With Exercise Cardiac PET in the United States.JACC. Case reports · 2025Article
- Technical evaluation of immediate back-to-back rest-stress positron emission tomography scanning withJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2025Article
- FDA Approval ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Comparative evaluation of a novel [European journal of nuclear medicine and molecular imaging · 2025Article
- Artificial Intelligence in Nuclear Cardiac Imaging: Novel Advances, Emerging Techniques, and Recent Clinical Trials.Journal of clinical medicine · 2025Review
- Flurpiridaz F 18: First Approval.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Review
- Expanding the repertoire ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2024Article
- The Role of Non-Invasive Multimodality Imaging in Chronic Coronary Syndrome: Anatomical and Functional Pathways.Diagnostics (Basel, Switzerland) · 2023Review
- Translational molecular imaging and drug development in Parkinson's disease.Molecular neurodegeneration · 2023Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesThis was a phase II trial to assess flurpiridaz F 18 for safety and compare its diagnostic performance for positron emission tomography (PET) myocardial perfusion imaging (MPI) with Tc-99m single-photon emission computed tomography (SPECT) MPI with regard to image quality, interpretative certainty, defect magnitude, and detection of coronary artery disease (CAD) (≥50% stenosis) on invasive coronary angiography (ICA).
backgroundIn pre-clinical and phase I studies, flurpiridaz F 18 has shown characteristics of an essentially ideal MPI tracer.
methodsOne hundred forty-three patients from 21 centers underwent rest-stress PET and Tc-99m SPECT MPI. Eighty-six patients underwent ICA, and 39 had low-likelihood of CAD. Images were scored by 3 independent, blinded readers.
resultsA higher percentage of images were rated as excellent/good on PET versus SPECT on stress (99.2% vs. 88.5%, p < 0.01) and rest (96.9% vs. 66.4, p < 0.01) images. Diagnostic certainty of interpretation (percentage of cases with definitely abnormal/normal interpretation) was higher for PET versus SPECT (90.8% vs. 70.9%, p < 0.01). In 86 patients who underwent ICA, sensitivity of PET was higher than SPECT (78.8% vs. 61.5%, respectively, p = 0.02). Specificity was not significantly different (PET: 76.5% vs. SPECT: 73.5%). Receiver-operating characteristic curve area was 0.82 ± 0.05 for PET and 0.70 ± 0.06 for SPECT (p = 0.04). Normalcy rate was 89.7% with PET and 97.4% with SPECT (p = NS). In patients with CAD on ICA, the magnitude of reversible defects was greater with PET than SPECT (p = 0.008). Extensive safety assessment revealed that flurpiridaz F 18 was safe in this cohort.
conclusionsIn this phase 2 trial, PET MPI with flurpiridaz F 18 was safe and superior to SPECT MPI for image quality, interpretative certainty, and overall CAD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.